4M Therapeutics CEO Pablo Lapuerta to Speak on "Opportunities for Biomarker Development in Neuroscience" at the 9th Annual Biomarker and Companion Diagnostics Conference
FOR IMMEDIATE RELEASE
4M Therapeutics CEO Pablo Lapuerta to Speak on "Opportunities for Biomarker Development in Neuroscience" at the 9th Annual Biomarker and Companion Diagnostics Conference in San Diego, California
Skillman, NJ – February 1st, 2024 – 4M Therapeutics Inc., an early stage biotechnology company developing therapies for central nervous system (CNS) disorders, is proud to announce that its CEO, Dr. Pablo Lapuerta, will be a featured speaker at the 9th Annual Biomarker and Companion Diagnostics Conference in San Diego, California. Dr. Lapuerta's presentation, titled "Opportunities for Biomarker Development in Neuroscience," will delve into the cutting-edge advancements and the future of personalized medicine in neurology.
As a respected leader in the biotech industry, Dr. Lapuerta brings nearly three decades of experience in clinical development and a deep commitment to enhancing patient care through scientific innovation. His talk will highlight the pivotal role of biomarkers in diagnosing, monitoring, and managing neurological diseases, with a particular focus on how these indicators are transforming the landscape of treatment options and patient outcomes.
"Biomarkers represent a critical frontier in neuroscience, offering the promise of more precise and effective interventions for complex conditions," said Dr. Lapuerta. "Our work at 4M Therapeutics is at the forefront of this exciting field, and I look forward to sharing our insights and discoveries with my colleagues at the conference."
The 9th Annual Biomarker and Companion Diagnostics Conference is renowned for gathering the world's leading experts in biomedical research, offering a platform for sharing the latest innovations and strategies in biomarker development. Dr. Lapuerta's presentation is scheduled for 11am PT on February 9th, 2024.
About 4M Therapeutics Inc.:
4M Therapeutics Inc. (4MTx) develops therapies for central nervous system (CNS) disorders. We focus on targets for a wide array of disorders and indications. We apply unique insights from our living human brain cell platform, which was developed through a collaborative effort between Harvard, MIT, and the University of Washington to identify and design more effective and safer therapeutics. For more information, visit www.4mtx.net.
For media inquiries, please contact:
Ben Williams, Chief Business Officer, 4M Therapeutics Inc.
ben@4mtx.net